Eisai 2012 First Quarter Aricept Sales Down 20%
This article was originally published in PharmAsia News
Eisai announced first quarter results August 1, and domestic sales of the company’s flagship Alzheimer drug Aricept, launched in November 2011 as a generic drug, decreased by 23.9% as prices of the drug decreased by 16%.
You may also be interested in...
Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.